stoxline Quote Chart Rank Option Currency Glossary
  
iTeos Therapeutics, Inc. (ITOS)
17.01  -0.55 (-3.13%)    07-17 16:00
Open: 17.31
High: 17.62
Volume: 305,153
  
Pre. Close: 17.56
Low: 16.52
Market Cap: 614(M)
Technical analysis
2024-07-17 5:28:16 PM
Short term     
Mid term     
Targets 6-month :  20.68 1-year :  24.16
Resists First :  17.7 Second :  20.68
Pivot price 15.47
Supports First :  14.83 Second :  13.06
MAs MA(5) :  16.7 MA(20) :  15.3
MA(100) :  13.74 MA(250) :  12.08
MACD MACD :  0.2 Signal :  0
%K %D K(14,3) :  91.3 D(3) :  90.5
RSI RSI(14): 61.1
52-week High :  18.75 Low :  8.19
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ITOS ] has closed below upper band by 10.8%. Bollinger Bands are 10.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.64 - 17.73 17.73 - 17.81
Low: 16.31 - 16.41 16.41 - 16.5
Close: 16.84 - 17.02 17.02 - 17.16
Company Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Headline News

Mon, 15 Jul 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Growth in Short Interest - MarketBeat

Mon, 08 Jul 2024
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism - Seeking Alpha

Mon, 08 Jul 2024
iTeos Announces First Patient Dosed in GALAXIES Lung-301 - GlobeNewswire

Mon, 08 Jul 2024
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK - StockTitan

Sun, 07 Jul 2024
iTeos Therapeutics (NASDAQ:ITOS) Shares Gap Down to $14.78 - Defense World

Wed, 05 Jun 2024
Should Shareholders Reconsider iTeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 36 (M)
Shares Float 25 (M)
Held by Insiders 0.6 (%)
Held by Institutions 99.9 (%)
Shares Short 2,240 (K)
Shares Short P.Month 2,160 (K)
Stock Financials
EPS -3.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.1
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -15.6 %
Return on Equity (ttm) -22.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.67
Qtrly Earnings Growth 0 %
Operating Cash Flow -110 (M)
Levered Free Cash Flow -89 (M)
Stock Valuations
PE Ratio -4.5
PEG Ratio 0
Price to Book value 1.12
Price to Sales 0
Price to Cash Flow -5.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android